Returns | 1W : 2.1% , 1M : -2.3%,1Y : 278.6% |
LT :   |
    Long Term Analysis
Fundamentals : Bad
Valuation : Average [Stock is fairly valued] Debt : High |
ST :   |
    Short Term Analysis
Quarterly Earnings Trend : Upward
Price Momentum : Mild Upward Pledged Shares : Average [>25% and <50%] |
Peers & Returns | 1W | 1M | 1Y |
MANGALAM DRUGS & ORGANICS LTD | 2.1% | -2.3% | 278.6% |
SUN PHARMACEUTICAL INDUSTRIES LTD | -1.1% | 0.1% | 30.6% |
DR REDDYS LABORATORIES LTD | -0.4% | -3.6% | 65.1% |
DIVIS LABORATORIES LTD | -0.6% | -3.9% | 94.4% |
CIPLA LTD | 0.8% | -2% | 72.3% |
BIOCON LTD | -12.3% | -18.6% | 51% |
AUROBINDO PHARMA LTD | 0.8% | 3.8% | 81.4% |
LUPIN LTD | 1.6% | 12.1% | 44.7% |
TORRENT PHARMACEUTICALS LTD | 2.1% | -3.9% | 37% |
Ratio | Value |
---|---|
P/E P/B P/S |
24.9
P/E Calculated based on EPS of 5.21
[ Mar2020 - Standalone Results ] 1.98
P/B Calculated based on Book Value of 65.67
[ Mar2020 - Standalone Results ] 0.64
P/S Calculated based on Revenues of 320.953 Cr
[ TTM - Standalone Results ] |
Model | Discount(-)/ Premium(+) |
---|---|
EV/EBIDTA EV/Sales Price/Sales |
56% -5% -6% |
Pledged Shares |
33.57 % |
---|---|
As on : Sep2020 | |
If less than 25% | Good |
If between 25% and 50% | Neutral |
If greater than 50% | Bad |